Top Markets
#1 Seeker Seeker +126.71%
#2 MowCat MowCat +106.93%
#3 AI XOVIA AI XOVIA +105.11%
#4 Helium Helium +79.97%
#5 Pons Pons +47.29%
#6 UnifAI Network UnifAI Network +35.07%
#7 Zora Zora +34.76%
#8 Zylo Ecosystem Zylo Ecosystem +20.92%
#9 Bounce Bounce +19.94%
#10 Tensor Tensor +17.83%
Coin of the day
Seeker Seeker
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Jacobio Pharmaceuticals Group Co., Ltd. Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

1167
Classificação em ações #11796
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm... Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Preço da ação
$0.84111496
Última sincronização: 2026-08-28
Valor de mercado
$657.90M
Variação (1 dia)
-0.75%
Variação (1 ano)
-19.13%
País
CN
Negociar Jacobio Pharmaceuticals Group Co., Ltd. (1167)

Categoria

Healthcare
Histórico de dividendos de Jacobio Pharmaceuticals Group Co., Ltd. (1167)
Jacobio Pharmaceuticals Group Co., Ltd. (símbolo da ação: 1167) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Jacobio Pharmaceuticals Group Co., Ltd. (1167) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH